1. Elder DP, Snodin DJ. Drug substance presented as sulfonic acid salts: overview of utility, safety and regulation. J Pharm Pharmacol. 2009;61:269–78.
2. Giordani A, Kobel W, Gally HU. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process. Eur J Pharm Sci. 2011;43:1–15.
3. Guorong ZHU et al. Method for synthesizing silodosin and intermediate thereof, 2018. WIPO, WO 2018/205919 A1. https://patentimages.storage.googleapis.com/03/95/7f/2b3cb399e7a248/WO2018205919A1.pdf. Accessed 30 Sept 2022.
4. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline M7 (R1)—Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, 2017. https://database.ich.org/sites/default/files/M7_R1_Guideline.pdf. Accessed 30 Sept 2022.
5. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline Q2 (R2): validation of analytical procedures: text and methodology, 2022. https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf. Accessed 30 Sept 2022.